For years, American policymakers, researchers, and security experts have warned the United States’s narrowing advantage in clinical research could threaten our dominance in medical innovation. Recognizing the need to address the bottlenecks that make initiating a new trial so costly and cumbersome, Health and Human Services Secretary Robert F. Kennedy Jr. recently announced a new effort to accelerate clinical research, dubbed Operation TrialBlazer.
Citing China’s rapid advances in early-stage trials and its growing share of new drug development, Operation TrialBlazer would streamline and modernize U.S. clinical research. Kennedy’s initiative would be a much-needed reprieve for the researchers and scientists developing the future of medicine — if he backs up his pledges with meaningful action that encourages innovation across the life sciences industry. Failure to do so quickly could squander our lead on China, a policy misstep an America First administration cannot afford.
